Influence of concomitant @entity117 or @entity229 on XXXX synovial fluid concentration.

@entity1 @entity32 @entity8834 @entity6822 @entity235 @entity229 @entity117 @entity230 @entity1499 @entity309
@entity1499 ( @entity6822 ) is currently being used in the treatment of @entity1 with @entity309 . The purpose of this study was to investigate the effect of two classes of drugs, @entity230 and @entity8834 , on @entity6822 synovial fluid concentrations. A novel @entity235 model of @entity32 was used, in which each animal served as its own control with both inflamed and normal knees in the same animal. After the 6-week immunization process, animals in each group received either no drug (control), @entity229 or @entity117 (low dose and high dose) for 1 week before @entity6822 . On the day of the study, each animal was given i.v. @entity6822 , and serial serum and synovial fluid samples were obtained. Laboratory, histologic and clinical observations supported the presence of @entity32 . The end-of-infusion synovial @entity6822 concentration in inflamed knees was significantly greater than in normal knees (P less than .05), but, 2 hr after the end of infusion, they were not different. The end-of-infusion ratio of synovial fluid @entity6822 concentration to serum @entity6822 concentration (both total and unbound) was significantly lower in the @entity229 group than in the other treatment groups (P less than .05). The end-of-infusion ratio of the @entity6822 synovial concentration in the inflamed knee compared with the normal knee at 2 hr was significantly lower in the @entity229 group than in the other three treatment groups (P less than .05). These results have therapeutic implications for the use of @entity6822 in treating @entity309 .
